[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 975
81. Ballard HO, Anstead MI, Shook LA: Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. Respir Res; 2007;8:41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Azithromycin reduces the severity of illness in patients with inflammatory lung disease such as cystic fibrosis and diffuse panbronchiolitis.
  • Bronchopulmonary dysplasia (BPD) is a pulmonary disorder which causes significant morbidity and mortality in premature infants.

  • Genetic Alliance. consumer health - Bronchopulmonary Dysplasia.
  • Hazardous Substances Data Bank. AZITHROMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatrics. 2004 Jul;114(1):e96-101 [15231980.001]
  • [Cites] Pediatrics. 2004 Jun;113(6):1709-14 [15173495.001]
  • [Cites] N Engl J Med. 1990 Dec 27;323(26):1793-9 [2247118.001]
  • [Cites] Antibiot Chemother (1971). 1991;44:94-8 [1801651.001]
  • [Cites] Pediatrics. 1994 May;93(5):712-8 [8165067.001]
  • [Cites] J Pediatr. 1994 Jun;124(6):956-61 [8201486.001]
  • [Cites] Pediatrics. 1996 Feb;97(2):210-5 [8584379.001]
  • [Cites] Pathology. 1996 Aug;28(3):266-9 [8912360.001]
  • [Cites] Pediatr Infect Dis J. 1997 Apr;16(4):364-9 [9109137.001]
  • [Cites] Pediatr Pulmonol. 1997 Nov;24(5):331-6 [9407566.001]
  • [Cites] J Perinatol. 1997 Nov-Dec;17(6):428-33 [9447527.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 1997 Nov;77(3):F198-201 [9462189.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 1998 Jan;78(1):F10-4 [9536833.001]
  • [Cites] J Antimicrob Chemother. 1998 Mar;41 Suppl B:47-50 [9579712.001]
  • [Cites] Antimicrob Agents Chemother. 1998 May;42(5):1290-2 [9593171.001]
  • [Cites] Pediatr Infect Dis J. 1998 Jul;17(7):615-20 [9686728.001]
  • [Cites] N Engl J Med. 1999 Jun 24;340(25):1962-8 [10379020.001]
  • [Cites] Thorax. 1999 Aug;54 Suppl 2:S58-62 [10451695.001]
  • [Cites] Pediatrics. 2004 Dec;114(6):1649-57 [15574629.001]
  • [Cites] Am J Obstet Gynecol. 2005 Apr;192(4):1179-86 [15846199.001]
  • [Cites] N Engl J Med. 2006 Jul 27;355(4):354-64 [16870914.001]
  • [Cites] Respir Res. 2006;7:134 [17064416.001]
  • [Cites] Pediatr Res. 1999 Dec;46(6):641-3 [10590017.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Jan;292(1):156-63 [10604943.001]
  • [Cites] Biol Neonate. 2001;79(3-4):205-9 [11275652.001]
  • [Cites] Pediatr Pulmonol. 2001 Jun;31(6):464-73 [11389580.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Jun;163(7):1723-9 [11401896.001]
  • [Cites] J Perinatol. 2001 Apr-May;21(3):156-60 [11503101.001]
  • [Cites] Respir Res. 2001;2(1):27-32 [11686862.001]
  • [Cites] Arch Dis Child. 2002 Jan;86(1):40-3 [11806882.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Feb;11(2):189-215 [11829712.001]
  • [Cites] Thorax. 2002 Mar;57(3):212-6 [11867823.001]
  • [Cites] Semin Neonatol. 2001 Aug;6(4):331-42 [11972434.001]
  • [Cites] Biol Neonate. 2002;82(1):22-8 [12119537.001]
  • [Cites] Eur J Pharmacol. 2002 Aug 30;450(3):277-289 [12208321.001]
  • [Cites] Pediatr Rev. 2002 Oct;23(10):349-58 [12359869.001]
  • [Cites] Semin Neonatol. 2003 Feb;8(1):63-71 [12667831.001]
  • [Cites] Chemotherapy. 2003 May;49(1-2):39-43 [12714809.001]
  • [Cites] J Perinatol. 2003 Apr-May;23(3):240-9 [12732863.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jul 1;168(1):121-5 [12672648.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2099-107 [14645637.001]
  • [Cites] J Orthop Res. 2004 Jan;22(1):21-9 [14656655.001]
  • [Cites] Chest. 2004 Feb;125(2 Suppl):41S-50S; quiz 51S [14872000.001]
  • [Cites] Thorax. 2004 Jun;59(6):540-1 [15170047.001]
  • [Cites] Agents Actions. 1988 Aug;25(1-2):124-31 [2847507.001]
  • (PMID = 17550598.001).
  • [ISSN] 1465-993X
  • [Journal-full-title] Respiratory research
  • [ISO-abbreviation] Respir. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents; 83905-01-5 / Azithromycin
  • [Other-IDs] NLM/ PMC1896160
  •  go-up   go-down


82. Lane R, He Y, Morris C, Leverenz JB, Emre M, Ballard C: BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord; 2009 Feb 15;24(3):392-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apolipoprotein E (APOE) epsilon4 and butyrylcholinesterase-K (BuChE-K) are associated with an increased risk for Alzheimer's disease.
  • The primary objective was to evaluate frequencies of these alleles in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD).
  • [MeSH-major] Apolipoprotein E4 / genetics. Butyrylcholinesterase / genetics. Cognition Disorders / epidemiology. Genotype. Hyperhomocysteinemia / epidemiology. Lewy Body Disease / epidemiology. Lewy Body Disease / genetics
  • [MeSH-minor] Aged. Female. Gene Frequency. Humans. Male. Neuroprotective Agents / therapeutic use. Neuropsychological Tests. Phenylcarbamates / therapeutic use. Psychomotor Disorders / diagnosis. Psychomotor Disorders / epidemiology. Randomized Controlled Trials as Topic. Rivastigmine. Severity of Illness Index

  • Genetic Alliance. consumer health - Dementias.
  • MedlinePlus Health Information. consumer health - Lewy Body Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Movement Disorder Society.
  • (PMID = 19006190.001).
  • [ISSN] 1531-8257
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0400074; United Kingdom / Medical Research Council / / G0502157; United States / NIA NIH HHS / AG / P50 AG005136; United States / NIA NIH HHS / AG / P50 AG005136-25
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoprotein E4; 0 / Neuroprotective Agents; 0 / Phenylcarbamates; EC 3.1.1.- / Butyrylcholinesterase; PKI06M3IW0 / Rivastigmine
  •  go-up   go-down


83. Connor-Ballard PA: Understanding and managing burn pain: Part 2. Am J Nurs; 2009 May;109(5):54-62; quiz 63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Acute Disease. Analgesia. Analgesics / therapeutic use. Anti-Infective Agents, Local / therapeutic use. Carboxymethylcellulose Sodium / therapeutic use. Causality. Drug Monitoring / nursing. Drug Therapy, Combination. Humans. Mafenide / therapeutic use. Nurse's Role. Polyesters / therapeutic use. Polyethylenes / therapeutic use. Practice Guidelines as Topic. Relaxation Therapy. Silver Sulfadiazine / therapeutic use. Skin Care / methods. Skin Care / nursing. Stress Disorders, Post-Traumatic / etiology. Stress Disorders, Post-Traumatic / prevention & control

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Pain.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19411907.001).
  • [ISSN] 1538-7488
  • [Journal-full-title] The American journal of nursing
  • [ISO-abbreviation] Am J Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acticoat; 0 / Analgesics; 0 / Anti-Infective Agents, Local; 0 / Polyesters; 0 / Polyethylenes; 58447S8P4L / Mafenide; 9004-32-4 / Carboxymethylcellulose Sodium; W46JY43EJR / Silver Sulfadiazine
  • [Number-of-references] 36
  •  go-up   go-down


8
Advertisement
4. Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten EC, van der Flier WM, Hsu C, Wu S, Lane R: Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin; 2008 Sep;24(9):2561-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rivastigmine demonstrated superiority over placebo on three measures of cognitive performance (Vascular Dementia Assessment Scale, Alzheimer's Disease Assessment Scale cognitive subscale, Mini-Mental State Examination; all p< or = 0.05, intent-to-treat population [ITT]), but not other outcomes.
  • Exploratory analyses indicated that older patients (> or =75 years old), assumed more likely to also have Alzheimer's disease (AD) pathology, demonstrated significant cognitive responses to rivastigmine and a safety profile similar to that seen in AD patients.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18674411.001).
  • [ISSN] 1473-4877
  • [Journal-full-title] Current medical research and opinion
  • [ISO-abbreviation] Curr Med Res Opin
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00099216
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neuroprotective Agents; 0 / Phenylcarbamates; 0 / Placebos; PKI06M3IW0 / Rivastigmine
  •  go-up   go-down


85. Zhang ZS, James AE, Huang Y, Ho WK, Sahota DS, Chen ZY: Quantification and characterization of aortic cholesterol in rabbits fed a high-cholesterol diet. Int J Food Sci Nutr; 2005 Aug;56(5):359-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification and characterization of aortic cholesterol in rabbits fed a high-cholesterol diet.
  • Determination of fat percentage of aortic intimal area stained by Sudan III is useful as an index of atherosclerosis in the rabbit animal model.
  • However, the determination of sudanophilic area of the thoracic aorta is two-dimensional and does not measure the third dimension of depth.
  • The objective of the present study was to quantify and characterize aortic lipids using the gas-liquid chromatographic (GLC) technique and to determine whether elevated measurements of total cholesterol and cholesteryl esters was correlated with increased measurements of sudanophilic area staining of the thoracic aorta in rabbits given either a normal chow or a 1% cholesterol diet.
  • The GLC results showed that there was a mean accumulation of 10.9 mg of cholesterol per gram of aortic tissue in the rabbits given a cholesterol diet (mean sudanophilic area of 23.8%).
  • In contrast, rabbits on a normal chow diet had only a deposition of 0.58 mg of cholesterol per gram of the aortic tissue diet (mean sudanophilic area of 1.4%).
  • The present study suggests that quantification of the aortic lipids can be performed by using GLC techniques and that it could be used as an alternative to the measurement of sudanophilic area when assessing the severity of atherosclerosis.
  • [MeSH-major] Aorta / chemistry. Atherosclerosis / etiology. Cholesterol / analysis
  • [MeSH-minor] Animals. Cholesterol Esters / analysis. Cholesterol, Dietary / administration & dosage. Chromatography. Fatty Acids, Nonesterified / analysis. Female. Male. Models, Animal. Rabbits. Staining and Labeling. Triglycerides / analysis. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236597.001).
  • [ISSN] 0963-7486
  • [Journal-full-title] International journal of food sciences and nutrition
  • [ISO-abbreviation] Int J Food Sci Nutr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholesterol Esters; 0 / Cholesterol, Dietary; 0 / Fatty Acids, Nonesterified; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


86. Tomofuji T, Azuma T, Kusano H, Sanbe T, Ekuni D, Tamaki N, Yamamoto T, Watanabe T: Oxidative damage of periodontal tissue in the rat periodontitis model: effects of a high-cholesterol diet. FEBS Lett; 2006 Jun 26;580(15):3601-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animal Feed. Animals. Deoxyguanosine / analogs & derivatives. Deoxyguanosine / metabolism. Disease Models, Animal. Fibroblasts. Interleukin-1 / metabolism. Male. Mitochondria / metabolism. Oxidation-Reduction / drug effects. Rats. Rats, Wistar. Triglycerides / blood. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750199.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Interleukin-1; 0 / Triglycerides; 0 / Tumor Necrosis Factor-alpha; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; 97C5T2UQ7J / Cholesterol; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


87. Paganini Stein FL, Schmidt B, Furlong EB, Souza-Soares LA, Soares MC, Vaz MR, Muccillo Baisch AL: Vascular responses to extractable fractions of Ilex paraguariensis in rats fed standard and high-cholesterol diets. Biol Res Nurs; 2005 Oct;7(2):146-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular responses to extractable fractions of Ilex paraguariensis in rats fed standard and high-cholesterol diets.
  • The authors investigated the vasorelaxant properties of the aqueous (Aq-EF) and acid n-butanolic (acn-BuOH) extractable fractions from Ilex paraguariensis leaves.
  • Perfusion pressure was evaluated using isolated and perfused mesenteric arterial beds (MABs) from rats fed hypercholesterolemic and standard diets.
  • Extract-induced vasorelaxation in the presence and absence of various inhibitors was examined following precontraction of the MABs with methoxamine (30 microM) solution.
  • In hypercholesterolemic-diet rats, relaxation in intact MABs was significantly decreased with ac-n-BuOH-EF bolus (300, 600, 900 microg) in comparison to those in standard-diet rats.
  • After the endothelium was stripped from the MABs, the vascular responses to ac-n-BuOH-EF and 900 microg bolus of Aq-EF were significantly changed.
  • Treatment of the MABs with an inhibitor of nitric oxide synthase, N(G)-nitro-L-arginine methylester hydrochloride (L-NAME, 10 mM), did not change either ac-n-BuOH-EF- or Aq-EF-induced vasodilation except for the 900 microg bolus of Aq-EF.
  • The guanilate cyclase inhibitor methylene blue (100 microM) did not affect vasodilation for either fraction in the MABs from the hypercholesterolemic-diet rats.
  • The chronic oral administration of I. paraguariensis extract in hypercholesterolemic-diet rats resulted in a significant reduction in serum levels of cholesterol and triglycerides.
  • These results suggest that I. paraguariensis ac-n-BuOH-EF and Aq-EF induce vasodilation in standard-diet rats in a dose-dependent manner and that the hypercholesterolemic diet substantially reduced the effect of ac-n-BuOH-EF on precontracted MABs.
  • [MeSH-major] Hypercholesterolemia / prevention & control. Ilex paraguariensis. Phytotherapy. Plant Extracts / pharmacology. Vasodilation / drug effects
  • [MeSH-minor] Analysis of Variance. Animals. Dose-Response Relationship, Drug. Endothelium, Vascular / drug effects. Endothelium, Vascular / metabolism. Male. Mesenteric Arteries / drug effects. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16267376.001).
  • [ISSN] 1099-8004
  • [Journal-full-title] Biological research for nursing
  • [ISO-abbreviation] Biol Res Nurs
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Plant Extracts
  •  go-up   go-down


88. Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Gilliland FD, Ballard-Barbash R: Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol; 2005 Feb 1;23(4):774-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors.
  • PURPOSE: Obese women and women who gain weight after a breast cancer diagnosis are at a greater risk for breast cancer recurrence and death compared with lean women and women who do not gain weight after diagnosis.
  • In this population-based study, we assessed weight and body fat changes from during the first year of diagnosis to during the third year after diagnosis, and whether any changes in weight and body fat varied by demographic, prognostic, and lifestyle factors in 514 women with incident Stage 0-IIIA breast cancer.
  • RESULTS: Women increased their weight and percent body fat by 1.7 +/- 4.7 kg and 2.1% +/- 3.9%, respectively, from during their first year of diagnosis to during their third year of diagnosis.
  • Greater increases in weight were observed among women diagnosed with a higher disease stage, younger age, being postmenopausal, and women who decreased their physical activity from diagnosis to up to 3 years after diagnosis (P for trend < .05).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 1999 Oct;57(3):285-90 [10617305.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):674-84 [10649263.001]
  • [Cites] Nature. 2000 Apr 6;404(6778):635-43 [10766250.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2751-7 [10870057.001]
  • [Cites] Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S498-504 [10993420.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89 [10995803.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2381-9 [11331316.001]
  • [Cites] Oncol Nurs Forum. 2001 May;28(4):675-84 [11383182.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):42-51 [11773152.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1128-43 [11844838.001]
  • [Cites] Cancer Pract. 2002 Mar-Apr;10(2):66-74 [11903271.001]
  • [Cites] N Engl J Med. 1999 Oct 7;341(15):1097-105 [10511607.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3504S-3507S [12421877.001]
  • [Cites] Sao Paulo Med J. 2002 Jul 4;120(4):113-7 [12436158.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1746-57 [12655532.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1961-6 [12743149.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1467-76 [14519753.001]
  • [Cites] Breast Cancer Res Treat. 2004 Feb;83(3):201-10 [14758090.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2248-53 [15126549.001]
  • [Cites] Med Sci Sports Exerc. 2004 Sep;36(9):1484-91 [15354027.001]
  • [Cites] J Natl Cancer Inst. 1981 Oct;67(4):785-9 [6944548.001]
  • [Cites] Breast Cancer Res Treat. 1985;5(2):195-200 [4016284.001]
  • [Cites] Am J Epidemiol. 1986 May;123(5):767-74 [3962960.001]
  • [Cites] Breast Cancer Res Treat. 1986;7(1):23-30 [3516262.001]
  • [Cites] Breast Cancer Res Treat. 1988 Apr;11(1):59-66 [3382763.001]
  • [Cites] Arch Intern Med. 1990 Mar;150(3):665-72 [2310286.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1327-34 [2199619.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1954-9 [2004310.001]
  • [Cites] Int J Epidemiol. 1991 Mar;20(1):151-6 [2066214.001]
  • [Cites] JAMA. 1995 Feb 8;273(6):461-5 [7654270.001]
  • [Cites] J Natl Cancer Inst. 1995 Mar 1;87(5):361-6 [7853417.001]
  • [Cites] J Am Diet Assoc. 1999 Oct;99(10):1212-21 [10524383.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3302-16 [12149305.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):120-9 [10458225.001]
  • [Cites] Ann Epidemiol. 1999 Apr;9(3):178-87 [10192650.001]
  • [Cites] Obes Res. 1998 Sep;6 Suppl 2:51S-209S [9813653.001]
  • [Cites] J Am Diet Assoc. 1997 May;97(5):519-26, 529; quiz 527-8 [9145091.001]
  • (PMID = 15681521.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / PC / PC035138-22; United States / NCI NIH HHS / CA / T32 CA09661; United States / NCRR NIH HHS / RR / M01-RR-00037; United States / NCI NIH HHS / CN / N01-CN-75036-20; United States / NCRR NIH HHS / RR / M01 RR000037; United States / NCI NIH HHS / PC / N01 PC035138-22; United States / NCI NIH HHS / CN / N01 CN005228; United States / NCI NIH HHS / CN / N01-CN-05228; United States / NICHD NIH HHS / HD / N01-HD-3-3175; United States / NCI NIH HHS / CA / T32 CA009661
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS250940; NLM/ PMC3000612
  •  go-up   go-down


89. Li J, Zhao SP, Yang J, Dong SZ, Zhou HN: [Effect of niacin on adiponectin levels in the adipocytes secretion in rabbits]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Jun;32(3):480-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of niacin on adiponectin levels in the adipocytes secretion in rabbits].
  • OBJECTIVE: To explore the effect of niacin on the serum adiponectin concentration in hypercholesterolemia rabbit and the adiponectin concentration secreted by adipocytes in normal rabbits.
  • METHODS: Ten male New Zealand white rabbits fed with high cholesterol diet for 8 weeks were randomly divided into 2 groups:.
  • (1) The high cholesterol group maintained a high cholesterol diet for 8 weeks. (2) The same cholesterol diet plus niacin (0.4g/kg*d ) were administrated for 6 weeks in the niacin group.
  • A control group was fed with normal diet for 14 weeks.
  • Subcutaneous adipose from the control group was collected for adipocyte culture.
  • Matured adipocytes were incubated with various concentrations of niacin (0, 0.25, 0.5, 1.0, and 2.0micromol/L).
  • Adiponectin concentrations in the serum and adipocyte culture supernatant were measured by enzyme-linked-immunosorbent assay.
  • RESULTS: Compared with the control group, rabbits in the high cholesterol group showed higher serum levels of total cholesterol, and low density lipoprotein cholesterol (LDL-C), all of which were significantly reduced by niacin treatment (P<0.01),and serum high density lipoprotein-cholesterol (HDL-C) significantly increased (P<0.01).
  • At 8th week, the mean adiponectin concentration of rabbits fed with high cholesterol diet was significantly lower than that of the control group[(1.268+/-0.039)mg/L vs.(1.449+/-0.107)mg/L,P<0.01].
  • Niacin treatment significantly elevated the serum adiponectin level which was positively related to HDL-C,and negatively related to TC and LDL-C.
  • Cell experiment in vitro indicated that niacin could significantly induce the adiponectin secretion of adipocytes in a dose-dependent manner.
  • CONCLUSION: Niacin can significantly promote the adiponectin secretion of adipocytes, suggesting that niacin probably has an ability of elevating the serum adiponectin level in addition to lipid-lowering effect.
  • [MeSH-major] Adipocytes / drug effects. Adiponectin / secretion. Niacin / pharmacology
  • [MeSH-minor] Animals. Cholesterol / blood. Cholesterol, Dietary / administration & dosage. Cholesterol, Dietary / toxicity. Cholesterol, HDL / blood. Cholesterol, LDL / blood. Dose-Response Relationship, Drug. Hypercholesterolemia / blood. Hypercholesterolemia / etiology. Hypercholesterolemia / prevention & control. Hypolipidemic Agents / pharmacology. Male. Rabbits. Random Allocation

  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. NICOTINIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611329.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Cholesterol, Dietary; 0 / Cholesterol, HDL; 0 / Cholesterol, LDL; 0 / Hypolipidemic Agents; 2679MF687A / Niacin; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


90. Zhang M, Ballard ME, Pan L, Roberts S, Faghih R, Cowart M, Esbenshade TA, Fox GB, Decker MW, Hancock AA, Rueter LE: Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. Brain Res; 2005 May 31;1045(1-2):142-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since H3 receptor (H3R) antagonists/inverse agonists can improve cognitive function in animal models, they may have the potential to be used as add-on therapy in the treatment of schizophrenia, a disease with significant cognitive deficits.
  • In order to clarify the basis of this finding, we replicated this result and extended the work with another imidazole and two non-imidazole H3R antagonists.

  • MedlinePlus Health Information. consumer health - Cold and Cough Medicines.
  • Hazardous Substances Data Bank. RISPERIDONE .
  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. HALOPERIDOL .
  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15910772.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Benzofurans; 0 / Drug Combinations; 0 / Histamine Antagonists; 0 / Imidazoles; 0 / Piperidines; 0 / Pyrrolidines; 0 / Receptors, Histamine H3; 0 / ciproxifan; 106243-16-7 / thioperamide; 820484N8I3 / Histamine; 86H6B395PI / benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)-; 9035-51-2 / Cytochrome P-450 Enzyme System; J6292F8L3D / Haloperidol; L6UH7ZF8HC / Risperidone; R9400W927I / Ketoconazole
  •  go-up   go-down


91. Stachon P, Missiou A, Walter C, Varo N, Colberg C, Wolf D, Buchner M, von Zur Mühlen C, Zirlik K, Bode C, Zirlik A: Tumor necrosis factor receptor associated factor 6 is not required for atherogenesis in mice and does not associate with atherosclerosis in humans. PLoS One; 2010;5(7):e11589
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several lines of evidence identified TRAF6 as a pro-inflammatory signaling molecule in vitro and we previously demonstrated overexpression of TRAF6 in human and Murine atherosclerotic plaques.
  • This study investigated the role of TRAF6-deficiency in mice developing atherosclerosis, a chronic inflammatory disease.
  • In accord, in a small clinical study TRAF6/GAPDH total blood RNA ratios did not differ between groups of patients with stable coronary heart disease (0.034+/-0.0021, N = 178), acute coronary heart disease (0.029+/-0.0027, N = 70), and those without coronary heart disease (0.032+/-0.0016, N = 77) as assessed by angiography.
  • CONCLUSION: Our study demonstrates that TRAF6 is not required for atherogenesis in mice and does not associate with clinical disease in humans.
  • [MeSH-minor] Animals. Aorta, Abdominal / metabolism. Cells, Cultured. Cholesterol / adverse effects. Cholesterol / blood. Collagen Type I / genetics. Collagen Type I / metabolism. Dietary Fats / adverse effects. Female. Flow Cytometry. Hematopoiesis / genetics. Hematopoiesis / physiology. Humans. Immunohistochemistry. Liver Transplantation. Mice. Mice, Mutant Strains. Polymerase Chain Reaction. Pregnancy. Receptors, LDL / genetics. Receptors, LDL / physiology. Weight Gain / drug effects

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Oct;21(10):1674-80 [11597944.001]
  • [Cites] EMBO J. 2001 Mar 15;20(6):1271-80 [11250893.001]
  • [Cites] Nature. 2002 Jul 25;418(6896):443-7 [12140561.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):868-74 [12490960.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):656-60 [12615675.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17278-82 [15001576.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10679-84 [15249654.001]
  • [Cites] J Immunol. 2004 Sep 1;173(5):2913-7 [15322147.001]
  • [Cites] Cardiovasc Res. 2004 Oct 1;64(1):154-64 [15364623.001]
  • [Cites] J Lipid Res. 1995 Nov;36(11):2320-8 [8656070.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):443-6 [8837778.001]
  • [Cites] J Biol Chem. 1996 Nov 15;271(46):28745-8 [8910514.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9792-6 [9275204.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):245-52 [9521319.001]
  • [Cites] J Exp Med. 1998 Jun 15;187(12):2097-101 [9625770.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):1015-24 [10215628.001]
  • [Cites] J Biol Chem. 1999 May 14;274(20):14246-54 [10318845.001]
  • [Cites] Genes Cells. 1999 Jun;4(6):353-62 [10421844.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2137-42 [15345516.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):1081-90 [15634933.001]
  • [Cites] Science. 2005 Apr 8;308(5719):248-51 [15705807.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1244-9 [15746436.001]
  • [Cites] Circulation. 2007 Mar 27;115(12):1571-80 [17372166.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2007 May;27(5):1101-7 [17332487.001]
  • [Cites] Adv Exp Med Biol. 2007;597:131-51 [17633023.001]
  • [Cites] J Exp Med. 2008 Feb 18;205(2):339-46 [18268038.001]
  • [Cites] Blood. 2008 May 1;111(9):4596-604 [18195092.001]
  • [Cites] Cell Signal. 2008 Sep;20(9):1679-86 [18603409.001]
  • [Cites] N Engl J Med. 2008 Nov 20;359(21):2195-207 [18997196.001]
  • [Cites] J Exp Med. 2010 Feb 15;207(2):391-404 [20100871.001]
  • [Cites] Circulation. 2010 Feb 23;121(7):e46-e215 [20019324.001]
  • [Cites] Science. 2010 Apr 9;328(5975):228-31 [20203013.001]
  • [Cites] Circulation. 2010 May 11;121(18):2033-44 [20421522.001]
  • [Cites] Nat Med. 2000 Feb;6(2):114 [10655072.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7458-63 [10861012.001]
  • [Cites] Oncogene. 2001 Oct 1;20(44):6482-91 [11607847.001]
  • (PMID = 20644648.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Dietary Fats; 0 / Receptors, LDL; 0 / TNF Receptor-Associated Factor 6; 97C5T2UQ7J / Cholesterol
  • [Other-IDs] NLM/ PMC2904388
  •  go-up   go-down


92. Yamamoto T, Tomofuji T, Tamaki N, Ekuni D, Azuma T, Sanbe T: Effects of topical application of lipopolysaccharide and proteases on hepatic injury induced by high-cholesterol diet in rats. J Periodontal Res; 2010 Feb;45(1):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Bacterial Proteins / adverse effects. Cholesterol, Dietary / adverse effects. Escherichia coli. Lipopolysaccharides / adverse effects. Liver / drug effects. Liver Diseases / etiology. Peptide Hydrolases / adverse effects. Periodontitis / etiology

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-Lysine .
  • Hazardous Substances Data Bank. CHOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19602105.001).
  • [ISSN] 1600-0765
  • [Journal-full-title] Journal of periodontal research
  • [ISO-abbreviation] J. Periodont. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Cholesterol, Dietary; 0 / Lipid Peroxides; 0 / Lipopolysaccharides; 0 / Reactive Oxygen Species; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; 9007-41-4 / C-Reactive Protein; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 3.4.- / Peptide Hydrolases; G1JO7801AE / Cholic Acid; G9481N71RO / Deoxyguanosine; K3Z4F929H6 / Lysine
  •  go-up   go-down


93. Küskü-Kiraz Z, Mehmetçik G, Dogru-Abbasoglu S, Uysal M: Artichoke leaf extract reduces oxidative stress and lipoprotein dyshomeostasis in rats fed on high cholesterol diet. Phytother Res; 2010 Apr;24(4):565-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Artichoke leaf extract reduces oxidative stress and lipoprotein dyshomeostasis in rats fed on high cholesterol diet.
  • Hypercholesterolemia and lipid peroxidation play complementary role in atherosclerosis.
  • Artichoke leaf extract (ALE) is rich in natural antioxidants and has a cholesterol-reducing effect.
  • However, there is no study investigating the effect of ALE on lipid levels and lipid peroxidation in experimental hypercholesterolemic conditions.
  • Rats were fed on 4% (w/w) cholesterol and 1% (w/w) cholic acid supplemented diet for 1 month.
  • ALE (1.5 g/kg/day) was given by gavage during the last 2 weeks.
  • Serum lipid composition, malondialdehyde (MDA) and diene conjugate (DC) levels and plasma antioxidant activity (AOA) were measured.
  • In addition, endogenous DC and copper-induced MDA levels were determined in apo B-containing lipoproteins (LDL+VLDL fraction).
  • Serum cholesterol and triglyceride levels and the ratio of cholesterol to HDL-cholesterol decreased due to ALE treatment in rats fed on HC diet.
  • Significant decreases in serum MDA and DC levels and increases in plasma AOA were detected in serum in ALE-treated hypercholesterolemic rats.
  • Endogenous DC and copper-induced MDA levels were also lower in LDL+VLDL fraction due to ALE-treatment in hypercholesterolemic rats.
  • Our results indicate that ALE may be useful for the prevention of hypercholesterolemia-induced pro-oxidant state in LDL+VLDL fraction and the reduction of increased serum cholesterol and triglyceride levels.
  • [MeSH-major] Cynara scolymus / chemistry. Hypolipidemic Agents / analysis. Lipid Metabolism / drug effects. Plant Extracts / pharmacology
  • [MeSH-minor] Animals. Apolipoproteins B / metabolism. Cholesterol, Dietary / administration & dosage. Drug Evaluation, Preclinical. Female. Lipid Peroxidation / drug effects. Lipids / blood. Oxidative Stress / drug effects. Plant Leaves / chemistry. Rats. Rats, Wistar

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 John Wiley & Sons, Ltd.
  • (PMID = 19777605.001).
  • [ISSN] 1099-1573
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apolipoproteins B; 0 / Cholesterol, Dietary; 0 / Hypolipidemic Agents; 0 / Lipids; 0 / Plant Extracts
  •  go-up   go-down


94. Souza PE, Rocha MO, Menezes CA, Coelho JS, Chaves AC, Gollob KJ, Dutra WO: Trypanosoma cruzi infection induces differential modulation of costimulatory molecules and cytokines by monocytes and T cells from patients with indeterminate and cardiac Chagas' disease. Infect Immun; 2007 Apr;75(4):1886-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trypanosoma cruzi infection induces differential modulation of costimulatory molecules and cytokines by monocytes and T cells from patients with indeterminate and cardiac Chagas' disease.
  • Here we demonstrate the immunomodulatory capacity of Trypanosoma cruzi, the causative agent of Chagas' disease, through its ability to induce differential expression of costimulatory molecules and cytokines by monocytes and T cells.
  • Costimulatory molecule and cytokine modulation was evaluated using cells from noninfected individuals and from patients with the asymptomatic indeterminate form and those with the severe cardiac clinical form of Chagas' disease.
  • These data show the ability of T. cruzi to actively change the expression of costimulatory molecules and cytokines, suggesting molecular mechanisms for the differential clinical evolution of human Chagas' disease.
  • [MeSH-major] Antigens, CD80 / biosynthesis. Antigens, CD86 / biosynthesis. Chagas Cardiomyopathy / immunology. Chagas Disease / immunology. Cytokines / biosynthesis. Monocytes / immunology. T-Lymphocytes / immunology

  • Genetic Alliance. consumer health - Chagas Disease.
  • MedlinePlus Health Information. consumer health - Chagas Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Immunol. 2000 Jan;51(1):91-7 [10632982.001]
  • [Cites] J Immunol. 1992 Oct 1;149(7):2378-84 [1356125.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1805-9 [10793092.001]
  • [Cites] Eur J Histochem. 2000;44(1):89-99 [10868297.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5062-8 [11046036.001]
  • [Cites] Infect Immun. 2001 May;69(5):3232-9 [11292745.001]
  • [Cites] Trends Parasitol. 2002 Jun;18(6):262-5 [12036740.001]
  • [Cites] Infect Immun. 2002 Aug;70(8):4638-42 [12117977.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11790-5 [12195015.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:e44-54 [12456332.001]
  • [Cites] Clin Exp Immunol. 2003 Jan;131(1):41-7 [12519384.001]
  • [Cites] Infect Immun. 2003 Mar;71(3):1185-93 [12595431.001]
  • [Cites] Immunol Rev. 2003 Apr;192:143-60 [12670402.001]
  • [Cites] BMC Immunol. 2002 Jul 6;3:8 [12100735.001]
  • [Cites] Braz J Med Biol Res. 2004 Apr;37(4):615-23 [15064826.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):4893-901 [15067068.001]
  • [Cites] Clin Exp Immunol. 2004 Jul;137(1):129-38 [15196253.001]
  • [Cites] Infect Immun. 2004 Sep;72(9):5283-91 [15322024.001]
  • [Cites] Prog Clin Parasitol. 1993;3:119-44 [8420601.001]
  • [Cites] Int Arch Allergy Immunol. 1992;99(1):8-15 [1336421.001]
  • [Cites] Annu Rev Immunol. 1993;11:191-212 [8386518.001]
  • [Cites] Am J Trop Med Hyg. 1993 May;48(5):637-44 [8517482.001]
  • [Cites] J Immunol. 1993 Oct 1;151(7):3489-99 [8397258.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;423(3):157-60 [7901937.001]
  • [Cites] Int Immunol. 1994 Apr;6(4):499-506 [8018591.001]
  • [Cites] J Exp Med. 1994 Aug 1;180(2):631-40 [7519245.001]
  • [Cites] J Immunol. 1994 Sep 1;153(5):1990-7 [7519638.001]
  • [Cites] Immunity. 1994 Aug;1(5):405-13 [7882171.001]
  • [Cites] Immunity. 1994 Dec;1(9):793-801 [7534620.001]
  • [Cites] Scand J Immunol. 1996 Jan;43(1):88-93 [8560201.001]
  • [Cites] Immunity. 1996 Jun;4(6):535-43 [8673700.001]
  • [Cites] Scand J Immunol. 1997 Jan;45(1):74-80 [9010503.001]
  • [Cites] Curr Opin Immunol. 1997 Jun;9(3):396-404 [9203422.001]
  • [Cites] Braz J Med Biol Res. 1998 Jan;31(1):111-5 [9686186.001]
  • [Cites] Microbes Infect. 2004 Nov;6(13):1133-44 [15488732.001]
  • [Cites] Am J Trop Med Hyg. 1986 May;35(3):505-11 [2422970.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8645-50 [10411929.001]
  • [Cites] J Endotoxin Res. 2004;10(6):425-30 [15588426.001]
  • [Cites] J Oral Pathol Med. 2005 May;34(5):312-7 [15817076.001]
  • [Cites] J Autoimmun. 2005 Mar;24(2):111-7 [15829403.001]
  • [Cites] Am J Pathol. 2005 Aug;167(2):305-13 [16049318.001]
  • [Cites] Immunol Lett. 2005 Nov 15;101(2):226-30 [16083969.001]
  • [Cites] Cell Mol Immunol. 2004 Feb;1(1):37-42 [16212919.001]
  • [Cites] Trends Parasitol. 2005 Dec;21(12):581-7 [16236550.001]
  • [Cites] Infect Immun. 2005 Dec;73(12):7853-9 [16299275.001]
  • [Cites] Scand J Immunol. 2006 Jan;63(1):70-8 [16398703.001]
  • [Cites] J Immunol. 1992 Mar 15;148(6):1792-6 [1541819.001]
  • [Cites] Mem Inst Oswaldo Cruz. 1999;94 Suppl 1:71-80 [10677693.001]
  • (PMID = 17283096.001).
  • [ISSN] 0019-9567
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD80; 0 / Antigens, CD86; 0 / Antigens, Differentiation; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / Cytokines
  • [Other-IDs] NLM/ PMC1865727
  •  go-up   go-down


95. Nishimura N, Yamamoto T, Ota T: Taurine feeding inhibits bile acid absorption from the ileum in rats fed a high cholesterol and high fat diet. Adv Exp Med Biol; 2009;643:285-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Taurine feeding inhibits bile acid absorption from the ileum in rats fed a high cholesterol and high fat diet.
  • We have previously reported that taurine-mediated reductions in plasma cholesterol in cholesterol-fed rats were caused by increased excretion of bile acids into feces.
  • In the present study, we examined the effect of taurine on bile acid secretion into bile and the absorption of bile acids from the ileum.
  • Male Wistar rats were divided into 2 groups, one group that was fed a diet containing 1% cholesterol (HC diet) and the other group fed a HC diet supplemented with 1% taurine for 2 weeks.
  • Bile acid concentrations in the mesenteric blood, the distal ileum and the colorectal digesta were determined.
  • Mesenteric bile acid concentration in the distal ileum was significantly lower in rats fed the taurine containing diet than in those fed only the HC diet.
  • Colorectal, but not distal ileal, bile acid concentration was significantly higher in rats fed the taurine diet than in those fed the HC diet.
  • However, the secretion of bile acids into the bile was similar in the two groups.
  • These results suggest that the absorption of bile acids from the distal ileum to the rectum is inhibited by taurine.
  • [MeSH-major] Bile Acids and Salts / metabolism. Cholesterol, Dietary / administration & dosage. Dietary Fats / administration & dosage. Ileum / metabolism. Taurine / administration & dosage
  • [MeSH-minor] Animals. Male. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • Hazardous Substances Data Bank. Taurine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19239159.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Cholesterol, Dietary; 0 / Dietary Fats; 1EQV5MLY3D / Taurine
  •  go-up   go-down


96. Mogi M, Iwai M, Chen R, Iwanami J, Ide A, Tsukuda K, Yoshii T, Horiuchi M: Amlodipine treatment reduces stroke size in apolipoprotein E-deficient mice. Am J Hypertens; 2006 Nov;19(11):1144-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Mice were subjected to middle cerebral artery (MCA) occlusion after being given a high-cholesterol (HCD) or normal diet for 10 weeks with or without amlodipine at a nonhypotensive dose of 3 mg/kg/day.
  • RESULTS: The ApoE KO mice given HCD for 10 weeks showed a larger ischemic lesion size than mice with a normal diet.
  • Amlodipine treatment in parallel with HCD feeding reduced the ischemic lesion size in ApoE KO mice.
  • Interestingly, amlodipine treatment for only the last 2 weeks was also effective in reducing the ischemic lesion size in HCD-fed ApoE KO mice.
  • Amlodipine treatment in HCD-fed ApoE KO mice also reduced superoxide production in the ischemic area of the brain.

  • MedlinePlus Health Information. consumer health - Ischemic Stroke.
  • MedlinePlus Health Information. consumer health - Stroke.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. AMLODIPINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17070425.001).
  • [ISSN] 0895-7061
  • [Journal-full-title] American journal of hypertension
  • [ISO-abbreviation] Am. J. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Calcium Channel Blockers; 11062-77-4 / Superoxides; 1J444QC288 / Amlodipine; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


97. Graça-de Souza VK, Monteiro-Góes V, Manque P, Souza TA, Corrêa PR, Buck GA, Ávila AR, Yamauchi LM, Pinge-Filho P, Goldenberg S, Krieger MA, Yamada-Ogatta SF: Sera of chagasic patients react with antigens from the tomato parasite Phytomonas serpens. Biol Res; 2010;43(2):233-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These flagellates can cause diseases in some plant families with a wide geographic distribution, which can result in great economic losses.
  • We have demonstrated previously that Phytomonas serpens 15T, a tomato trypanosomatid, shares antigens with Trypanosoma cruzi, the agent of human Chagas disease.
  • Herein, two-dimensional gel electrophoresis (2-DE) and mass spectrometry (MS) were used to identify proteins of P. serpens 15T that are recognized by sera from patients with Chagas disease.
  • These results generated a collection of proteins that can provide a starting point to obtain insights into antigenic cross reactivity among trypanosomatids and to explore P. serpens antigens as candidates for vaccine and immunologic diagnosis studies.
  • [MeSH-major] Antigens, Protozoan / immunology. Chagas Disease / immunology. Leishmania / immunology. Lycopersicon esculentum / parasitology. Trypanosoma cruzi / immunology

  • MedlinePlus Health Information. consumer health - Chagas Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21031268.001).
  • [ISSN] 0717-6287
  • [Journal-full-title] Biological research
  • [ISO-abbreviation] Biol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Antigens, Protozoan
  •  go-up   go-down


98. Cai D, Holm JM, Duignan IJ, Zheng J, Xaymardan M, Chin A, Ballard VL, Bella JN, Edelberg JM: BDNF-mediated enhancement of inflammation and injury in the aging heart. Physiol Genomics; 2006 Feb 14;24(3):191-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aging is associated with shifts in autocrine and paracrine pathways in the cardiac vasculature that may contribute to the risk of cardiovascular disease in older persons.
  • Overall, these studies suggest that age-associated changes in BDNF-Trk B pathways may predispose the aging heart to increased injury after acute myocardial infarction and potentially contribute to the enhanced severity of cardiovascular disease in older individuals.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352696.001).
  • [ISSN] 1531-2267
  • [Journal-full-title] Physiological genomics
  • [ISO-abbreviation] Physiol. Genomics
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG-20320; United States / NIA NIH HHS / AG / AG-20918; United States / NHLBI NIH HHS / HL / HL-67839
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Brain-Derived Neurotrophic Factor; 0 / Peptide Library; 0 / Receptors, Tumor Necrosis Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 2.7.10.1 / Receptor, trkB
  •  go-up   go-down


99. Tintle N, Lantieri F, Lebrec J, Sohns M, Ballard D, Bickeböller H: Inclusion of a priori information in genome-wide association analysis. Genet Epidemiol; 2009;33 Suppl 1:S74-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six contributions to Genetic Analysis Workshop 16 Group 11 applied novel or recently proposed methods to GWAS of rheumatoid arthritis and heart disease related phenotypes.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] J Evol Biol. 2005 Sep;18(5):1368-73 [16135132.001]
  • [Cites] Am J Hum Genet. 2007 Dec;81(6):1278-83 [17966091.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):55-65 [16369572.001]
  • [Cites] Rheumatology (Oxford). 2006 Apr;45(4):365-8 [16418195.001]
  • [Cites] Bioinformatics. 2007 Apr 15;23(8):980-7 [17303618.001]
  • [Cites] BMC Genet. 2007;8:20 [17490491.001]
  • [Cites] Nature. 2007 Jun 7;447(7145):661-78 [17554300.001]
  • [Cites] BMC Bioinformatics. 2007;8:242 [17612399.001]
  • [Cites] Am J Hum Genet. 2007 Aug;81(2):397-404 [17668389.001]
  • [Cites] N Engl J Med. 2007 Sep 6;357(10):977-86 [17804842.001]
  • [Cites] N Engl J Med. 2007 Sep 20;357(12):1199-209 [17804836.001]
  • [Cites] Nat Genet. 2007 Oct;39(10):1208-16 [17873875.001]
  • [Cites] Hum Mol Genet. 2007 Oct 15;16 Spec No. 2:R220-5 [17597095.001]
  • [Cites] Genet Epidemiol. 2007 Dec;31(8):871-82 [17654612.001]
  • [Cites] Hum Hered. 2008;65(3):129-41 [17934316.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1216-23 [18794853.001]
  • [Cites] Genet Epidemiol. 2008 Nov;32(7):658-68 [18481796.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D258-61 [14681407.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Nat Genet. 2004 May;36(5):431-2 [15118671.001]
  • [Cites] Arthritis Rheum. 1987 Nov;30(11):1205-13 [2446635.001]
  • [Cites] Heredity (Edinb). 2005 Sep;95(3):221-7 [16077740.001]
  • [Cites] BMC Bioinformatics. 2008;9:469 [18986519.001]
  • [Cites] Genet Epidemiol. 2009 Apr;33(3):198-206 [18979499.001]
  • [Cites] Hum Genet. 2009 Apr;125(3):305-18 [19184112.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • (PMID = 19924705.001).
  • [ISSN] 1098-2272
  • [Journal-full-title] Genetic epidemiology
  • [ISO-abbreviation] Genet. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NHGRI NIH HHS / HG / R15-HG004543; United States / NIGMS NIH HHS / GM / R01 GM031575-25; United States / NIGMS NIH HHS / GM / R01 GM031575; United States / NHGRI NIH HHS / HG / R15 HG004543; United States / NHGRI NIH HHS / HG / R15 HG004543-01S1
  • [Publication-type] Congresses; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS219654; NLM/ PMC2922922
  •  go-up   go-down


100. Yoshida M, Kimura H, Kyuki K, Ito M: Combined effect of probucol and insulin on cataracts of diabetic rats fed a high cholesterol diet. Eur J Pharmacol; 2005 Apr 18;513(1-2):159-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined effect of probucol and insulin on cataracts of diabetic rats fed a high cholesterol diet.
  • We investigated the effects of long-term treatment with probucol, a hypolipidemic agent with antioxidative action, insulin, or their combination on cataracts of streptozotocin-induced diabetic rats fed a high cholesterol diet.
  • Each rat was checked for cataracts at 0, 1, 2, 4, 8, 12 and 15 weeks after streptozotocin injection.
  • Cataracts were observed from 8 weeks in untreated hypercholesterolemic and diabetic rats and the incidence of catarats increased to 100% by 15 weeks.
  • The incidence of cataracts in rats treated with probucol, insulin and their combination was first seen at 12, 12 and 15 weeks, respectively, and was 86%, 63% and 33%, respectively, at 15 weeks.
  • The preventive effects of both agents alone and their combination on the cataracts were confirmed by histopathological evaluation of eyeballs.
  • The combined treatment with both agents markedly improved hyperglycemia, hyperlipidemia and increased serum lipid peroxide levels.
  • These results indicate that the combined treatment with probucol and insulin is useful in preventing the development and progression of diabetic cataracts.
  • [MeSH-major] Cataract / prevention & control. Cholesterol, Dietary / administration & dosage. Diabetes Mellitus, Experimental / complications. Insulin / pharmacology. Probucol / pharmacology
  • [MeSH-minor] Animals. Blood Glucose / metabolism. Body Weight / drug effects. Cholesterol / blood. Drug Therapy, Combination. Eating / drug effects. Eye / drug effects. Eye / pathology. Lipid Peroxides / blood. Male. Rats. Rats, Sprague-Dawley. Survival Rate. Time Factors. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Cataract.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869753.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Cholesterol, Dietary; 0 / Insulin; 0 / Lipid Peroxides; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol; P3CTH044XJ / Probucol
  •  go-up   go-down






Advertisement